Table of Contents
Chemotherapy Research and Practice
Volume 2012, Article ID 901320, 10 pages
Review Article

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

1Aerodigestive and Thoracic Tumor Program, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
3UCSF School of Medicine, University of California San Francisco, San Francisco, CA 94115, USA

Received 14 May 2012; Accepted 22 July 2012

Academic Editor: Basil El-Rayes

Copyright © 2012 Scott A. Kono et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [3 citations]

The following is the list of published articles that have cited the current article.

  • Gordon A. G. McKenzie, Emma E. Hinsley, Keith Hunter, and Daniel W. Lambert, “The endothelin axis in head and neck cancer: a promising therapeutic opportunity?,” Journal of Oral Pathology & Medicine, vol. 43, no. 6, pp. 395–404, 2014. View at Publisher · View at Google Scholar
  • Xin Wu, Jingwen Huang, Lei Liu, Hongmei Li, Ping Li, Jing Zhang, and Li Xie, “Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.,” Medicine, vol. 95, no. 39, 2016. View at Publisher · View at Google Scholar
  • Lei Liu, Yuquan Wei, Jingwen Huang, Jing Zhang, and Changle Shi, “Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: A meta-analysis,” BMC Cancer, vol. 16, no. 1, 2016. View at Publisher · View at Google Scholar